mdlinx mdlinx

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.


* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 
Comments:

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons

Ascher–Svanum H et al. – Using treatment–completion rates as a proxy measure of medication effectiveness, olanzapine long–acting injection did not differ significantly from risperidone long–acting injection when including all eligible studies. However, the findings of this exploratory analysis should be interpreted with caution, considering the methodological limitations of these indirect, cross–study comparisons.

Methods
  • Indirect, cross–study comparisons between olanzapine long–acting injection and risperidone long–acting injection used 12–month treatment–completion rates, because discontinuation of an antipsychotic for any cause is a recognized proxy measure of the medication's effectiveness in treating schizophrenia.
  • Following a systematic review of the literature, two indirect comparisons were conducted using open–label, single–cohort studies in which subjects were stabilized on an antipsychotic medication before depot initiation.
  • The first analysis compared olanzapine long–acting injection (one study) with pooled data from nine identified risperidone long–acting injection studies.
  • The second analysis was a “sensitivity analysis,” using only the most similar studies, one for olanzapine long–acting injection and one for risperidone long–acting injection, which shared near–identical study designs and involved study cohorts with near–identical patient characteristics.
  • Pearson Chi–square tests assessed group differences on treatment–completion rates.

Results
  • Comparison of olanzapine long–acting injection data (931 patients) with the pooled data from the nine risperidone long–acting injection studies (3950 patients) provided almost identical 12–month treatment–completion rates (72.7% versus 72.4%; P = 0.87).
  • When the two most similar studies were compared, the 12–month completion rate for olanzapine long–acting injection was significantly higher than for risperidone long–acting injection (81.3% versus 47.0%; P < 0.001).
  • However, any conclusions drawn from this comparison may be limited by differences in the studies' geographic catchment areas.
[more...]

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close